Join to view full profile
1950 Circle of HopeClinic 1aSalt Lake City, UT 84112
Phone+1 801-585-0100
Fax+1 801-585-7902
Dr. Whisenant is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
University of ColoradoResidency, Internal Medicine, 1998 - 2001- University of California San Francisco School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - Present
UT State Medical License 2005 - 2028
CO State Medical License 2000 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2012, 2014, 2017
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma Start of enrollment: 2018 Apr 11
- Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy Start of enrollment: 2019 Dec 15
Publications & Presentations
PubMed
- 1 citationsAuthor Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.Conan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, Katrin P Guillen, Mona Foth
Nature Medicine. 2025-06-01 - A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembroliz...Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth Boucher, James Marvin
BMC Research Notes. 2023-02-16 - 14 citationsDiscrepancies between tumor genomic profiling and germline genetic testing.K Pauley, C Koptiuch, S Greenberg, W Kohlmann, J Jeter
ESMO Open. 2022-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
